Advertisement
Product › Details
AC101 / HL22 (Alligator Biosience / AbClon / Shanghai Henlius Biotech)
Next higher product group | antibody cancer drug | |
Status | 2019-12-17 development pc | |
Organisation | Shanghai Henlius Biotech Inc. | |
Organisation 2 | Alligator Bioscience AB (Nasdaq Stockholm: ATORX) | |
Group | Alligator Bioscience (Group) | |
Alligator Bioscience AB. (12/17/19). "Press Release: First Patient Dosed with ATOR-1017 Developed for Metastasized Cancer". Lund.
Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced that the first patient has been successfully dosed in the Phase I study with the wholly owned 4-1BB antibody ATOR-1017, which is being developed for the treatment of metastasized cancer.
The Phase I study is a dose escalation study in patients with advanced cancer and this is the first time ATOR-1017 is being evaluated in humans. The study will be conducted at three different clinics in Sweden and include up to 50 patients. The primary objective of the study is to assess the safety and tolerability of ATOR-1017 and to determine the recommended dose for the subsequent Phase II studies.
ATOR-1017 activates 4-1BB receptors which increases the ability of the immune system to detect and kill tumor cells. This makes 4-1BB a particularly attractive target for cancer immunotherapy. ATOR-1017 has a unique profile related to the fact that its immune-stimulatory function is stronger in areas where immune cells are abundant, notably in tumors. This creates an opportunity for a strong immune activation that can increase efficacy and reduce side effects for the patient.
“In the preclinical studies, ATOR-1017 has showed a strong and long-lasting immune response, and even created immunity to cancer, while minimizing the side effects through tumor-directed immune activation. This profile puts ATOR-1017 at the forefront of the field and it will be very exciting to follow the continued clinical development “, said Per Norlén, CEO of Alligator Bioscience.
For further information, please contact:
Cecilia Hofvander, Director Investor Relations & Communications
Phone +46 46 540 82 06
E-mail: cecilia.hofvander@alligatorbioscience.com
The information was submitted for publication, through the agency of the contact persons set out above, at 1:00 p.m. CET on December 17, 2019.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s growing pipeline includes six lead clinical and preclinical drug candidates: mitazalimab (ADC-1013), ATOR-1015, ATOR-1017, ALG.APV-527 (co-developed with Aptevo Therapeutics Inc.), ATOR-1144 and AC101 (in clinical development by Shanghai Henlius Biotech Inc.). Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 55 employees. For more information, please visit http://www.alligatorbioscience.com.
Record changed: 2023-07-10 |
Advertisement
More documents for antibody cancer drug
- [1] StromaCare. (2/13/24). "Press Release: StromaCare Appoints Georges Rawadi as CEO". Lyon....
- [2] MorphoSys AG. (2/5/24). "Press Release: MorphoSys Enters into Business Combination Agreement to Be Acquired by Novartis for € 2.7 Billion Equity Value. Tafasitamab Sold to Incyte". Planegg....
- [3] Catalym GmbH. (1/9/24). "Press Release: Catalym Appoints Drug Development Leader Roy Baynes to its Board of Directors and Strengthens Scientific Advisory Board with Three Accomplished Lung and Bladder Cancer Specialists". Mainz....
- [4] Human Immunology Biosciences, Inc. (HI-Bio). (1/4/24). "Press Release: HI-Bio Announces $95 Million Series B Financing to Advance Targeted Therapies for Immune-Mediated Diseases". South San Francisco, CA....
- [5] Merck KGaA. (1/4/24). "Press Release: Merck Expands Colorectal Cancer Portfolio Through Licensing Agreement with Inspirna [Not intended for UK-, US- or Canada-based media]". Darmstadt....
- [6] SwiftPharma B.V.. (11/13/23). "Press Release: SwiftPharma and PlantForm Corporation Target Blockbuster Cancer Drug with New Contract Manufacturing Agreement for Plant-made Biosimilars". Ghent & Toronto, ON....
- [7] BioNTech SE. (10/31/23). "Press Release: BioNTech to Present Clinical and Preclinical Data Updates Across Multiple Immuno-Oncology Programs at 2023 SITC Annual Meeting". Mainz....
- [8] Antiverse Ltd.. (10/16/23). "Press Release: Antiverse and GlobalBio, Inc. Extend Collaboration to Advance Antibody Cancer Therapeutics". Cardiff & Cambridge, MA....
- [9] BeiGene, Ltd.. (9/19/23). "Press Release: BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody Tevimbra (tislelizumab)". Basel & Beijing & Cambridge, MA....
- [10] Invios GmbH. (9/5/23). "Press Release: Invios Starts Further Clinical Trial of APN401, Novel Cell Therapy Against Solid Cancers, and Secures Major Austrian Grant Funding". Vienna....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top